H-Ras Activation Assay Kit (ab211158)
Key features and details
- Sample type: Adherent cells, Suspension cells, Tissue
Overview
-
Product name
H-Ras Activation Assay Kit
See all GTPase HRAS kits -
Sample type
Tissue, Adherent cells, Suspension cells -
Species reactivity
Reacts with: Mouse, Rat, Human -
Product overview
H-Ras Activation Assay Kit (ab211158) uses Raf-1 RBD agarose beads to selectively isolate and pull-down the active form of Ras from cell or tissue lysates. The precipitated GTP-Ras is subsequently detected by western blot analysis using an anti-H-Ras specific rabbit polyclonal antibody, which reacts with the human, mouse and rat protein.
Features: 1) non radioactive assay format; 2) fast results: 1 hour assay plus electrophoresis/blotting time; 3) includes Cdc42 positive control; 4) pink colored agarose beads for easy identification during washing and aspiration steps.
-
Notes
Small GTP-binding proteins (or GTPases) are a family of proteins that serve as molecular regulators in signaling transduction pathways.
Ras, a 21 kD protein, regulates a variety of biological response pathways that include cell growth, cell transformation and tumor invasion. Like other small GTPases, Ras regulates molecular events by cycling between an inactive GDP-bound form and an active GTP-bound form. In its active GTP-bound state, Ras binds specifically to the Ras-binding domain (RBD)of Raf1 to control downstream signaling cascades. Since defects in Ras signaling may result in malignant transformation, the activation of Ras proteins is tightly controlled in normal cells.
The 3 Ras genes in human are H-Ras, N-Ras and K-Ras – it is estimated now that approximately 20% – 25% of all human tumors have activating mutations in one of the Ras genes.
H-Ras (Harvey Rat Sarcome Viral Oncogene Homolog), also known as transforming protein p21, is associated with Costello Syndrome and phakomatosis pigmentokeratotica.
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 20 tests 100X GDP 1 x 50µl 100X GTPyS 1 x 50µl 5X Assay/Lysis Buffer 1 x 30ml ab211176 - Raf-1 RBD Agarose Beads 1 x 800µl Anti-H-Ras Rabbit polyclonal antibody 1 x 40µl H-Ras Immunoblot Positive Control 1 x 100µl -
Research areas
-
Function
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. -
Involvement in disease
Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC). -
Sequence similarities
Belongs to the small GTPase superfamily. Ras family. -
Post-translational
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation. -
Cellular localization
Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus. - Information by UniProt
-
Alternative names
- C BAS/HAS
- c H ras
- C HA RAS1
see all -
Database links
- Entrez Gene: 3265 Human
- Entrez Gene: 15461 Mouse
- Entrez Gene: 293621 Rat
- Omim: 190020 Human
- SwissProt: P01112 Human
- SwissProt: Q61411 Mouse
- SwissProt: P20171 Rat
- Unigene: 37003 Human
see all